Why CSL and 2 other healthcares stars could be ASX shares to buy

CSL Limited (ASX:CSL) shares are one of three in the healthcare sector that I think investors ought to consider buying right now…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Yesterday I wrote about how I'm very bullish on the tech sector over the long term due to the quality on offer inside it.

Another area of the market that I'm especially bullish on over the long term is the healthcare sector.

This is due my belief that ageing populations, increased chronic disease burden, and better technologies will lead to increasing demand for healthcare services over the next decade or two.

With that in mind, here are three healthcare shares that I think could be great long-term investments:

CSL Limited (ASX: CSL)

This global biotech giant has been one of the best and most consistent performers on the Australian share market over the last decade, delivering average earnings growth of 13.3% per annum and an average total shareholder return of 20.1% per annum. Due to its strong core business, expanding plasma collection network, and lucrative pipeline of products under development, I believe it is well placed to continue this solid form over the next decade.

Pro Medicus Limited (ASX: PME)

Although its shares trade on sky high multiples and therefore carry a lot of risk, I believe this healthcare technology company could still be a great long term investment. Pro Medicus is a leading provider of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions to healthcare organisations across the globe. There is a significant market opportunity for these systems and I expect Pro Medicus to capture a good slice of it over the long term due to the quality of its offering.

ResMed Inc (ASX: RMD)

This sleep treatment specialist's share price has fallen heavily over the last two trading sessions after its solid second quarter result still fell short of the market's lofty expectations. I believe the selloff was an overreaction and has created a buying opportunity for investors that are prepared to make a long-term investment. Especially given its leading position in a sleep treatment market expected to grow strongly over the next decade.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

a man in a business suit points his finger amid a digitised map of the globe suspended in the air in front of him, complete with graphs, digital code and glyphs to indicate digital assets.
Investing Strategies

Future focus: How to diversify your portfolio with ASX AI ETFs

Looking for a simple and effective way to capitalise on the growth of AI technologies across global markets?

Read more »

chart showing an increasing share price
Growth Shares

Buy these excellent ASX growth shares for 15% to 20% returns

Analysts think big returns could be on the cards for owners of these shares.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Growth Shares

These ASX 200 growth shares could rise 12% to 30%

Analysts think big returns could be on offer from these shares.

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Growth Shares

Hoping to beat the ASX 200? I'd consider buying these 3 ASX shares

Analysts think these shares can outperform the market.

Read more »

a happy investor with a wide smile points to a graph that shows an upward trending share price
Growth Shares

5 top ASX growth shares to buy in April

Analysts think growth investors should be buying these shares.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Growth Shares

These mid-cap ASX shares could rise 20% to 50%

Goldman Sachs is tipping these stocks as buys.

Read more »

A happy boy with his dad dabs like a hero while his father checks his phone.
Growth Shares

2 ASX growth shares that could turn $1,000 into $10,000 by 2034

I think these two stocks have a shot at being 10-baggers.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Growth Shares

These top ASX 200 growth shares can rise 10% to 50%

Analysts see major upside ahead for these buy-rated shares.

Read more »